E
Calliditas Therapeutics AB (publ)
CALT
NASDAQ
E
Sell
6/3/2024Downgrade
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D- on 6/3/2024 due to a large decline in the solvency index and valuation index. Debt to equity increased from 2.12 to 2.69.
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D- on 6/3/2024 due to a large decline in the solvency index and valuation index. Debt to equity increased from 2.12 to 2.69.
D
Sell
2/12/2024Upgraded
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D- from E+ on 2/12/2024 due to a noticeable increase in the total return index and volatility index.
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D- from E+ on 2/12/2024 due to a noticeable increase in the total return index and volatility index.
E
Sell
8/18/2023Downgrade
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D- on 8/18/2023 due to a decline in the volatility index, total return index and valuation index.
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D- on 8/18/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
8/10/2023Upgraded
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D- from E+ on 8/10/2023 due to an increase in the volatility index.
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D- from E+ on 8/10/2023 due to an increase in the volatility index.
E
Sell
6/29/2023Downgrade
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D- on 6/29/2023 due to a noticeable decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0067 to -$0.3345, EBIT declined 428.77% from $5.19M to -$17.06M, and operating cash flow declined 203.39% from $21.48M to -$22.2M.
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D- on 6/29/2023 due to a noticeable decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0067 to -$0.3345, EBIT declined 428.77% from $5.19M to -$17.06M, and operating cash flow declined 203.39% from $21.48M to -$22.2M.
D
Sell
3/14/2023Downgrade
Calliditas Therapeutics AB (publ) (CALT) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
Calliditas Therapeutics AB (publ) (CALT) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/9/2023Upgraded
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D on 02/08/2023.
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D on 02/08/2023.
D
Sell
12/29/2022Upgraded
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D from D- on 12/29/2022 due to an increase in the total return index and volatility index.
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D from D- on 12/29/2022 due to an increase in the total return index and volatility index.
D
Sell
11/16/2022Downgrade
Calliditas Therapeutics AB (publ) (CALT) was downgraded to D- from D on 11/16/2022 due to a decline in the growth index, solvency index and valuation index. The quick ratio declined from 5.04 to 4.19, and debt to equity increased from 0.65 to 0.67.
Calliditas Therapeutics AB (publ) (CALT) was downgraded to D- from D on 11/16/2022 due to a decline in the growth index, solvency index and valuation index. The quick ratio declined from 5.04 to 4.19, and debt to equity increased from 0.65 to 0.67.
D
Sell
5/23/2022Upgraded
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D from D- on 5/23/2022 due to a large increase in the growth index. Total revenue increased 51.04% from $3.52M to $5.32M, earnings per share increased from -$0.4876 to -$0.423, and EBIT increased 8.68% from -$24.41M to -$22.3M.
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D from D- on 5/23/2022 due to a large increase in the growth index. Total revenue increased 51.04% from $3.52M to $5.32M, earnings per share increased from -$0.4876 to -$0.423, and EBIT increased 8.68% from -$24.41M to -$22.3M.
D
Sell
5/4/2022Upgraded
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D- from E+ on 05/04/2022.
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D- from E+ on 05/04/2022.
E
Sell
4/20/2022Downgrade
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index.
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index.
D
Sell
11/22/2021Upgraded
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D- from E+ on 11/22/2021 due to a substantial increase in the solvency index, growth index and volatility index. Earnings per share increased from -$0.3804 to $0.0243, EBIT increased 104.79% from -$18.94M to $908.1, and operating cash flow increased 75.67% from -$15.8M to -$3.84M.
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D- from E+ on 11/22/2021 due to a substantial increase in the solvency index, growth index and volatility index. Earnings per share increased from -$0.3804 to $0.0243, EBIT increased 104.79% from -$18.94M to $908.1, and operating cash flow increased 75.67% from -$15.8M to -$3.84M.
E
Sell
11/8/2021Downgrade
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
10/22/2021Downgrade
Calliditas Therapeutics AB (publ) (CALT) was downgraded to D- from D on 10/22/2021 due to a major decline in the solvency index and volatility index. The quick ratio declined from 7.4 to 5.81.
Calliditas Therapeutics AB (publ) (CALT) was downgraded to D- from D on 10/22/2021 due to a major decline in the solvency index and volatility index. The quick ratio declined from 7.4 to 5.81.
D
Sell
7/1/2021Upgraded
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D from D- on 7/1/2021 due to a large increase in the solvency index and valuation index.
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D from D- on 7/1/2021 due to a large increase in the solvency index and valuation index.
D
Sell
3/1/2021Upgraded
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D- from E+ on 3/1/2021 due to an increase in the valuation index.
Calliditas Therapeutics AB (publ) (CALT) was upgraded to D- from E+ on 3/1/2021 due to an increase in the valuation index.
E
Sell
12/1/2020Upgraded
Calliditas Therapeutics AB (publ) (CALT) was upgraded to E+ from E on 12/1/2020 due to a large increase in the total return index.
Calliditas Therapeutics AB (publ) (CALT) was upgraded to E+ from E on 12/1/2020 due to a large increase in the total return index.
E
Sell
9/3/2020None
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E from U on 09/03/2020.
Calliditas Therapeutics AB (publ) (CALT) was downgraded to E from U on 09/03/2020.
